Bellevue Group AG decreased its position in Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 2.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 154,909 shares of the medical equipment provider’s stock after selling 4,498 shares during the quarter. Bellevue Group AG owned 0.21% of Align Technology worth $50,798,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Align Technology by 0.3% during the first quarter. Vanguard Group Inc. now owns 8,375,147 shares of the medical equipment provider’s stock worth $2,746,378,000 after purchasing an additional 25,362 shares in the last quarter. Brown Advisory Inc. boosted its stake in Align Technology by 41.4% in the fourth quarter. Brown Advisory Inc. now owns 1,509,080 shares of the medical equipment provider’s stock valued at $413,488,000 after acquiring an additional 441,754 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Align Technology by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 1,132,742 shares of the medical equipment provider’s stock valued at $371,449,000 after buying an additional 11,800 shares during the last quarter. Norges Bank purchased a new stake in shares of Align Technology in the fourth quarter valued at about $223,610,000. Finally, Allianz Asset Management GmbH raised its holdings in shares of Align Technology by 11.1% in the fourth quarter. Allianz Asset Management GmbH now owns 668,823 shares of the medical equipment provider’s stock valued at $183,258,000 after buying an additional 67,088 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.
Align Technology Stock Down 2.5 %
Shares of ALGN traded down $5.60 during mid-day trading on Friday, hitting $220.45. 1,185,768 shares of the company’s stock were exchanged, compared to its average volume of 776,117. The firm has a fifty day moving average of $249.03 and a two-hundred day moving average of $280.62. Align Technology, Inc. has a twelve month low of $176.34 and a twelve month high of $413.20. The stock has a market cap of $16.60 billion, a price-to-earnings ratio of 36.32, a P/E/G ratio of 4.09 and a beta of 1.66.
Wall Street Analysts Forecast Growth
ALGN has been the subject of several analyst reports. Stifel Nicolaus cut their price target on shares of Align Technology from $400.00 to $350.00 and set a “buy” rating for the company in a report on Thursday. UBS Group increased their target price on shares of Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a report on Monday, April 15th. Piper Sandler lowered their price target on shares of Align Technology from $330.00 to $315.00 and set an “overweight” rating on the stock in a research report on Thursday. OTR Global restated a “mixed” rating on shares of Align Technology in a research report on Tuesday, June 4th. Finally, Morgan Stanley decreased their target price on shares of Align Technology from $328.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Align Technology currently has an average rating of “Hold” and an average price target of $322.78.
Get Our Latest Stock Analysis on ALGN
Align Technology Company Profile
Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.
Read More
- Five stocks we like better than Align Technology
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Why Call Options Volume for These 2 Stocks Spiked Together
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN – Free Report).
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.